Innova Captab Ltd Stock Price Today (NSE: INNOVACAP)

Innova Captab Ltd

974.25+4.70 (+0.48%)
Market Closed

Fundamental Score

...

Innova Captab Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Innova Captab Ltd share price today is 974.25, up +0.48% on NSE/BSE as of 31 July 2026. Innova Captab Ltd (INNOVACAP) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of 5.68K (Cr). The 52-week high for INNOVACAP share price is 1034.85 and the 52-week low is 622.00. At a P/E ratio of 40.45x, INNOVACAP is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 13.69% and a debt-to-equity ratio of 0.32.

Innova Captab Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
1034.85
Low
942.00
Volume
45.5K
Change
+0.09%

Innova Captab Ltd share price chart: 0.09% return over the past month. 52-week high ₹1034.85, 52-week low ₹622.00.

Innova Captab Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
969.50980.40960.55974.2526.79K (Cr)
975.15983.15961.05969.5517.92K (Cr)
963.90974.70959.35968.6523.31K (Cr)
979.90979.90953.30957.2515.74K (Cr)
948.00975.90948.00970.4043.74K (Cr)
965.80981.90956.80980.0523.55K (Cr)
962.00976.00953.05973.2538.63K (Cr)
1018.001019.70957.10962.7058.37K (Cr)
991.451024.70990.951011.3032.34K (Cr)
1000.001034.85987.00991.4570.26K (Cr)

Innova Captab Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
981.001034.85942.00974.25-0.69%
855.001031.50836.80978.45+14.44%
790.00918.00790.00850.40+7.65%
685.00763.40670.00752.05+9.79%
623.00729.00622.00689.85+10.73%
694.90737.00659.55668.25-3.84%
720.10764.95624.00695.20-3.46%
725.00776.90660.00720.10-0.68%
822.40834.00702.95718.25-12.66%
860.00881.00792.90831.10-3.36%
901.00944.00816.60853.00-5.33%
912.60954.00870.60902.05-1.16%

Returns & Performance

Poor

Return on Equity (ROE)

13.69%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

14.96%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

13.96%

Average operating profit margin over 5 years

Dividend Yield

0.20%

Annual dividend as % of current share price

Innova Captab Ltd Valuation Check

Poor

Price to Earnings (P/E)

40.45x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Mid-cap
Balance of growth potential and stability.

Shareholding Pattern

Excellent

Promoter Holding

50.90%

% shares held by company founders/management

Poor

FII Holding

0.34%

% shares held by foreign institutional investors

Good

DII Holding

19.92%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

28.78%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

42.28%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

31.75%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

-38.84%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

32.48%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.32x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

12.10x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-226.13 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Innova Captab Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of INNOVACAP across key market metrics for learning purposes.

Positive Indicators

7 factors identified

Robust Profit Growth (28.78%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (42.28%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (31.75% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Strong Profit Growth Track Record (32.48% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Strong Interest Coverage (12.10x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (50.90%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Premium Valuation Risk (P/E: 40.45x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Weak Earnings Growth (-38.84% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Negative Free Cash Flow (₹-226.13 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Innova Captab Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Innova Captab Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
64.1/100
974
₹5678.13
40.5
Average
13.69%
Average
14.96%
Average
0.3
Excellent
32.48%
Excellent
31.75%
Excellent
0.20%
66.4/100
1991
₹468821.49
37.7
Average
15.95%
Good
20.53%
Excellent
0.1
Excellent
16.75%
Excellent
11.78%
Good
0.82%
56.3/100
8056
₹193163.97
73.6
Average
16.53%
Good
21.96%
Excellent
0.0
Excellent
5.71%
Good
8.67%
Good
0.41%
51.4/100
5123
₹169902.02
77.5
Average
27.43%
Excellent
15.19%
Good
1.8
Average
12.07%
Good
11.80%
Good
0.76%
Cipla Ltd...
CIPLA500087
40.2/100
1473
₹116131.81
30.5
Average
11.60%
Average
15.49%
Good
0.0
Excellent
9.94%
Good
8.01%
Good
0.90%
74.1/100
1078
₹115375.77
21.3
Average
21.25%
Excellent
21.14%
Excellent
0.5
Excellent
18.77%
Excellent
12.45%
Good
0.09%
Lupin Ltd...
LUPIN500257
83.4/100
2415
₹113976.53
20.0
Average
28.68%
Excellent
29.93%
Excellent
0.3
Excellent
37.02%
Excellent
13.02%
Good
0.72%
61.5/100
2470
₹105053.91
52.3
Average
13.12%
Average
13.50%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%
41/100
1148
₹102660.46
25.6
Average
11.22%
Average
13.04%
Average
0.2
Excellent
15.44%
Excellent
12.09%
Good
0.65%
24.6/100
1580
₹90035.87
25.4
Average
10.06%
Average
12.80%
Average
0.2
Excellent
0.80%
Average
6.32%
Good
0.26%
34.1/100
1816
₹84016.75
93.9
Average
18.30%
Good
17.76%
Good
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%

Innova Captab Ltd PE Ratio History

Historical price-to-earnings ratio for INNOVACAP — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202522.41₹720.1032.1x
FY 202418.66₹1115.4059.8x
FY 202311.87₹541.4045.6x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Innova Captab Ltd Quarterly Performance

Latest quarterly metrics for INNOVACAP — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

42.28%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

28.78%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

31.75%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

32.48%

Compounded annual net profit growth over 5 years

Innova Captab Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for INNOVACAP — calculated from daily price history

47RSI 14
Neutral — RSI 47

Momentum is balanced — neither overbought nor oversold.

SMA 50
933
▲ Price above SMA 50 — Short-term bullish
SMA 200
783
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
49K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Innova Captab Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Innova Captab Ltd (INNOVACAP) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Innova Captab Ltd

About INNOVACAP (Innova Captab Ltd)

Innova Captab Ltd is a dynamic pharmaceutical entity with a broad spectrum of capabilities, ranging from advanced research and development to efficient manufacturing and widespread... distribution. Their core strength lies in providing comprehensive contract development and manufacturing organization (CDMO) services to domestic pharmaceutical giants, facilitating the production of diverse drug formulations. This positions them as a crucial partner in the pharmaceutical supply chain, contributing significantly to the availability and accessibility of essential medications. Innova Captab's operational framework is designed to meet the evolving demands of the pharmaceutical landscape, enabling them to adapt to market dynamics and regulatory changes effectively. Beyond their CDMO services, Innova Captab also specializes in developing and marketing a robust portfolio of generic formulations. These products encompass a wide range of therapeutic areas, catering to prevalent health needs. Their generic drug offerings include crucial medications such as cephalosporins, targeting bacterial infections, and proton pump inhibitors (PPIs) for managing gastric conditions. Additionally, their product line extends to anticholinergics and heparin-based medications, along with NSAIDs, analgesics, and antipyretics for pain and fever management. The inclusion of anticold and antiallergic drugs further highlights their commitment to providing comprehensive healthcare solutions. Innova Captab's commitment to quality and innovation is evident in their end-to-end approach, from drug conception to commercialization. By integrating research, development, manufacturing, and distribution under one umbrella, they ensure stringent quality control and efficient operational processes. This integrated model, coupled with their expanding portfolio of generic formulations and robust CDMO services, positions Innova Captab as a key player in the pharmaceutical sector, both within India and in the global arena. They aim to continue growing and adding value to the broader healthcare ecosystem.

Company Details

Symbol:INNOVACAP
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Manoj Kumar Lohariwala
Executive Chairman
Mr. Vinay Kumar Lohariwala
MD & Director
Mr. Lokesh Bhasin
Chief Financial Officer

INNOVACAP Share Price: Frequently Asked Questions

What is the current share price of Innova Captab Ltd?

Innova Captab Ltd (INNOVACAP) trades at ₹974.25 on NSE and BSE. Market cap ₹5.68K (Cr). Educational data only.

What is the P/E ratio of Innova Captab Ltd?

Innova Captab Ltd has a P/E of 40.45x vs industry average 34.89x.

What is the Bull Run score for Innova Captab Ltd?

Innova Captab Ltd has a Bull Run score of 64.1/100 based on 25+ financial parameters.

Does Innova Captab Ltd pay dividends?

Innova Captab Ltd has a dividend yield of 0.20%. Past dividends don't guarantee future payments.

What is the ROE of Innova Captab Ltd?

Innova Captab Ltd has ROE of 13.69%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Innova Captab Ltd?

Innova Captab Ltd has debt-to-equity of 0.32.

Is Innova Captab Ltd a good investment?

Bull Run gives Innova Captab Ltd a score of 64.1/100. This is not investment advice — consult a SEBI-registered advisor.